Todd Arden
About Todd Arden
Todd Arden has served as an independent director of eHealth, Inc. (EHTH) since September 17, 2025, appointed as H.I.G.’s board designee; he currently sits on the Compensation, Nominating & Corporate Governance, and Government & Regulatory Affairs Committees . He is a credit and special situations investor and former Senior Managing Director and Co‑Chief Credit Officer at Black Diamond Capital Management (2016–2020), with prior roles at CCMP Capital (Chief Investment Officer – Octagon Credit Opportunities) and Angelo, Gordon & Co.; he holds a BA in Economics from Northwestern, an MBA from Columbia, and is a CFA charterholder . His tenure on EHTH’s board began in September 2025; age not disclosed in company materials .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Black Diamond Capital Management | Senior Managing Director & Co‑Chief Credit Officer | Jan 2016 – Mar 2020 | Led underwriting and credit exposures for alternative asset manager |
| CCMP Capital Advisors (Octagon Credit Opportunities) | Chief Investment Officer | Oct 2012 – Nov 2014 | Built credit opportunities strategy within a PE platform |
| Angelo, Gordon & Co. | Managing Director, Distressed Securities | Mar 2000 – Jun 2012 | Led investments in restructurings; served on multiple post‑reorg boards |
| AIG Global Investment Corp | Senior Research/Portfolio roles (High Yield) | Prior to 2000 (dates not specified) | High yield credit research/PM |
| Troubh Partners LP | Senior Equity Analyst | Prior to 2000 (dates not specified) | Equity analysis in distressed contexts |
| Arthur Andersen & Co. (NY) | Manager, Financial Consulting Services | Prior to 2000 (dates not specified) | Distressed/litigation support |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Quantum Corporation | Director | Appointed Jun 10, 2024 | Appointed by Quantum; public company directorship |
| Global Clean Energy Holdings | Director (prior) | Not disclosed | Disclosed by EHTH; dates not provided |
| Private company boards | Director | Current | Serves on several private boards (names not disclosed) |
Board Governance
- Committee assignments: Compensation Committee (member), Nominating & Corporate Governance Committee (member), Government & Regulatory Affairs Committee (member) .
- Designation: Appointed as H.I.G.’s board designee following Aaron Tolson’s resignation; H.I.G. retains nomination rights under the Investment Agreement .
- Independence considerations: Company risk factors caution that interests of an H.I.G.-designated director may differ from other security holders .
- Attendance baseline: Board met nine times in 2024; all directors met ≥75% attendance except one Compensation Committee instance, but Arden joined in Sept 2025 (no 2024 attendance data for him) .
Fixed Compensation
| Component | Structure | Amount/Terms |
|---|---|---|
| Company cash retainer – Board | Annual retainer (pro rata for 2025 start) | $100,000 cash annual retainer for non‑employee directors (effective mid‑2024 program) |
| Company cash retainers – Committees | Annual retainers (pro rata) | Compensation Committee member $7,500; Nominating & Corporate Governance member $5,000; Government & Regulatory Affairs member $5,000 |
| Company equity – Initial grant | Time‑based RSUs | Grant‑date value $150,000 of RSUs at appointment; vest in three equal annual installments over three years, subject to continued service |
| Travel expense reimbursement | Policy | Reasonable, customary, documented travel reimbursed by Company |
| Annual director equity cadence (program) | Time‑based RSUs | Standard annual RSUs valued at $175,000 with quarterly vesting cadence until next AGM; initial grants $175,000 vest annually over three years (program baseline) |
| H.I.G. third‑party compensation | Cash from H.I.G. (while serving as director) | H.I.G. agreed to pay $35,000 per month less the company cash paid for that month, plus a $5,000 per diem under specified circumstances |
Note: EHTH’s director program was amended in June 2024 to increase cash retainers and reduce annual equity grant size by $25,000; the table reflects current program levels .
Performance Compensation
| Element | Metrics | Terms |
|---|---|---|
| Director equity performance conditions | None disclosed for non‑employee directors | Director grants are time‑based RSUs; accelerated vesting upon change in control; no PSU/option performance metrics applied to director awards |
Other Directorships & Interlocks
| Company | Relationship to EHTH | Role/Committees |
|---|---|---|
| H.I.G. Capital (Echelon Health SPV, LP) | Significant preferred equity investor with nomination rights; designated Arden to EHTH board | Not a board seat; investor designation; H.I.G. has additional rights due to covenant non‑compliance (see Risk Indicators) |
| Quantum Corporation | Unrelated to EHTH operations | Public company director (committees not disclosed) |
| Global Clean Energy Holdings | Unrelated to EHTH operations | Prior public company director |
Expertise & Qualifications
- Credit/distressed investing and capital markets: senior leadership at Black Diamond (Co‑Chief Credit Officer) and Angelo, Gordon; CIO role for Octagon Credit Opportunities at CCMP .
- Board experience: service on multiple public and private boards, including Quantum Corporation and prior service at Global Clean Energy Holdings .
- Education/credentials: BA (Northwestern), MBA (Columbia), CFA charterholder .
Equity Ownership
| Item | Detail |
|---|---|
| Initial beneficial ownership (Form 3) | Reported no securities beneficially owned as of Sept 17, 2025 event date |
| New‑director RSU grant | $150,000 grant‑date value of time‑based RSUs; vesting annually over three years |
| Stock ownership guidelines | Non‑employee directors expected to hold a value equal to 5x annual board retainer (currently $375,000); achieve by June 30 following 4th anniversary; retention of 75% net shares until compliant |
| Hedging/pledging | Insider Trading Policy prohibits pledging, hedging, short sales and derivatives on Company stock |
Insider Filings
| Form | Filing/Effective Date | Key Facts |
|---|---|---|
| Form 3 | Filed Sept 19, 2025 (event 09/17/2025) | Initial statement as Director; Table I shows “No securities beneficially owned” |
Governance Assessment
-
Positives
- Deep credit, restructuring, and capital allocation expertise; relevant to oversight of capital structure, financing, and risk management .
- Broad committee engagement (Compensation, Nominating & Corporate Governance, Government & Regulatory Affairs), suggesting active role in key oversight areas .
- Formal director ownership guidelines and anti‑hedging/pledging policy support alignment with long‑term shareholders .
- No Company‑related related‑party transactions requiring Item 404(a) disclosure were reported upon his appointment .
-
Risk indicators and RED FLAGS
- H.I.G. Influence and third‑party compensation: Arden was appointed as H.I.G.’s designee and receives monthly/ per‑diem compensation directly from H.I.G., in addition to Company retainers; Company risk factors warn an H.I.G.-designated director’s interests may diverge from common shareholders, and H.I.G. holds significant voting and preferential rights through Series A Preferred Stock (including redemption and consent rights) .
- Covenant non‑compliance enhanced H.I.G. rights: EHTH’s prior failures to maintain the Minimum Asset Coverage Ratio (as of 9/30/2023) and Minimum Liquidity (as of 11/30/2024) entitle H.I.G. to additional rights (e.g., additional director nomination, approval rights over budget, key hires, and indebtedness) while it owns ≥30% of original preferred—implications for board autonomy and potential conflicts .
- Capital structure overhang: Series A Preferred votes on an as‑converted basis and is convertible; potential dilution and governance influence risk .
Director Compensation Context (Program Benchmarks)
| Element | 2024 Program Level |
|---|---|
| Non‑employee Board retainer (cash) | $75,000 (raised by $25,000 in June 2024) |
| Board Chair additional retainer | $50,000 |
| Committee Chair retainers | Audit $25,000; Compensation $15,000; Nominating & Corporate Governance $10,000; Government & Regulatory Affairs $10,000 |
| Committee member retainers | Audit $10,000; Compensation $7,500; Nominating & Corporate Governance $5,000; Government & Regulatory Affairs $5,000 |
| Annual equity (directors) | RSUs $175,000 grant-date value; time‑based vesting; accelerated vesting on change in control |
| Annual compensation cap | $750,000 per director ($1,000,000 in initial year) |
Say‑on‑Pay & Shareholder Feedback (Context)
- 2024 say‑on‑pay approval received approximately 82.5% of votes cast (up from ~76.4% in 2023), reflecting improved support for compensation governance .
Board Governance Details (Company Reference)
- Board met nine times in 2024; independent directors meet in regular executive sessions .
- Committee charters and oversight scope: Audit (financial/cyber/ERM), Compensation (exec/director pay, clawback), Nominating & Corporate Governance (board composition/ESG/conflicts), Government & Regulatory Affairs (regulatory/public policy) .
Notes on Independence, Attendance, and Engagement
- Independence status is not specifically stated for Arden; however, risk factors note that interests of an H.I.G.-designated director may differ from other shareholders, and he receives third‑party compensation from H.I.G. alongside Company director pay .
- Attendance: No Arden‑specific attendance disclosure yet; he joined September 2025; 2024 attendance baselines provided above .